Wilmington-based Pharmaceutical Product Development, Inc. announced today that the sale of the company has been completed. As of Monday at 4 p.m., the company’s stock (PPDI) will no longer be traded on the NASDAQ. On its last day of being publically traded, the company’s stock ranged from $33.19 to $33.25.

Pursuant to the terms of the merger agreement, PPD’s shareholders are entitled to receive $33.25 in cash, without interest, less any applicable withholding taxes, for each share of PPD common stock owned by them.

Shareholders of record will receive a letter of transmittal and instructions on how to surrender their shares of PPD common stock in exchange for the merger consideration. They should wait to receive the letter of transmittal before surrendering their shares, according to company officials.

The contract research organization has been acquired by affiliates of The Carlyle Group and affiliates of Hellman & Friedman in an all-cash transaction valued at about $3.9 billion. The Carlyle Group is a global alternative asset manager with over $153 billion of assets under management and Hellman & Friedman LLC is a private equity investment firm with offices in San Francisco, New York and London that has raised and managed, through its affiliated funds, over $25 billion of committed capital since 1984.

As previously reported, the transaction was approved by PPD shareholders at a special meeting on November 30.

Morgan Stanley & Co. LLC served as financial advisor, and Lazard provided a fairness opinion, to the board of directors of PPD in connection with the transaction. Wyrick Robbins Yates & Ponton LLP and Skadden, Arps, Slate, Meagher & Flom LLP served as legal advisors to PPD in connection with the transaction. Latham & Watkins LLP, Simpson Thacher & Bartlett LLP and Covington & Burling LLP served as legal counsel, and Credit Suisse served as financial advisor, to Carlyle and Hellman & Friedman in connection with the transaction.